MiraLAX Generics Get FDA Reprieve Despite Bayer Objections
Sales of generic versions of popular constipation drug MiraLAX will be allowed for an extra six months, the U.S. Food and Drug Administration revealed Friday, rejecting opposition from Bayer AG and...To view the full article, register now.
Already a subscriber? Click here to view full article